A new study from the Centre for Cancer Immunology has gained novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated.
The work, published in the journal Communications Biology , investigates a class of receptors present on immune cells called TNFR. These receptors, such as CD40, 4-1BB and OX40, are key in helping the immune system fight pathogens and cancer cells.
Accordingly, antibody drugs which are designed to specifically target and activate these receptors (called agonists) have been developed for cancer treatment.
The mechanism by which these receptors are activated on the cell surface is important for designing optimal drug formats; however, to date it is not fully understood. Previous work showed that receptor clustering, redistribution of receptors dispersed over the cell surface into localised clusters, is essential for TNF receptor activation, and it is commonly believed that larger clusters induce more potent activation.
Led by Dr Ben Yu and Professor Mark Cragg, with colleagues across the University and at ONI UK ,the study employed a set of unique reagents developed at Southampton targeting CD40, 4-1BB and OX40. It also used a new super-resolution microscopy acquired through funding from the Mark Benevolent Fund, to address how differential receptor clustering mediates receptor activity.
In the study, TNF receptor activation absolutely required receptor clustering but interestingly, disproved the commonly held belief that larger clusters induce more receptor activation. Rather, the study finds that agonists that induced smaller clusters – but with higher receptor density mediated better TNF receptor activity than those which induced larger clusters.
In addition to receptor size, one of the most potent antibody agonists targeting CD40 induced a novel rod-shaped clustering structure, which could potentially explain the super-agonistic nature of that antibody.
These findings add significant insight into how TNF receptors cluster to mediate immune activation and will help guide future development of therapeutic antibodies targeting TNF receptors.
The study was funded by Cancer Research UK.